80 results
Page 2 of 4
8-K
EX-99.1
vhd0hf4 pcruhiohv2v
10 May 21
FibroGen Reports First Quarter 2021 Financial Results
4:07pm
8-K
EX-99.1
190pe342y6byrsq7
6 Apr 21
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat
4:59pm
8-K
EX-99.1
u7zr8uc
1 Mar 21
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm
8-K
r2ail og3y
1 Dec 20
Departure of Directors or Certain Officers
8:05am
8-K
EX-99.1
f8hx1
5 Nov 20
FibroGen Reports THIRD Quarter 2020 Financial Results
4:05pm
8-K
EX-99.1
m9kplnzkvphk
6 Aug 20
FibroGen Announces New Appointments to its Board of Directors
4:06pm
8-K
EX-99.1
zy59y2a8 r79
2 Mar 20
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
4:06pm
8-K
EX-99.1
verza
30 Jan 20
Astellas Submits Supplemental New Drug Application for Approval of
4:40pm
8-K
EX-99.2
e95xv v1wab
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
EX-99.1
brlt cerw8
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
ra584e
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
EX-99.1
jxas5x1zi5y8cv1h
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
5toz3k8m lchsh
8 Nov 19
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
2:00pm